Safety and Clinical Performance of the Protecta ICD and CRT-D

Inclusion Criteria: * Patients meeting one of the following criteria can be included in Phase I of the study: * Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D) * Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant) * Patients meeting one of the following criteria can be included in Phase II of the study: * Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device * Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D * Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant Exclusion Criteria: * Patients with a mechanical tricuspid heart valve * Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study * Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients * Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc) * Patients anticipated not being able to complete the study * Patients unwilling to provide written informed consent